Molecule News and Research

RSS

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Study finds IAP enzyme maintains normal microbial population in gastrointestinal system

An enzyme that keeps intestinal bacteria out of the bloodstream may also play an important role in maintaining the normal microbial population of the gastrointestinal system.

19 Oct 2010

Researchers to identify protein-recycling mechanism of TB bacteria

Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory and Stony Brook University have discovered a key difference in the way human cells and Mycobacterium tuberculosis bacteria, which cause TB, deliver unwanted proteins marked with a "kiss of death" sequence to their respective cellular recycling factories.

18 Oct 2010

IDRI's TB vaccine protects against drug-resistant tuberculosis

The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

18 Oct 2010

Researchers identify new paradigm for regulation of alternative splicing

How a T cell decides to make protein X, Y, or Z can have profound effects for fighting foreign invaders or staving off dire autoimmune reactions. Researchers at the University of Pennsylvania School of Medicine have identified the steps that control how different forms of an immune cell protein called CD45, which is critical for activating the immune system when faced with pathogens, are controlled in the arc of a body's immune response.

18 Oct 2010

New insights into HIV infection process may allow antiviral drug development

New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

15 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.

14 Oct 2010

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.

14 Oct 2010

Scientists unveil quality control mechanism of immune system to destroy pathogens

An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.

14 Oct 2010

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

XenoPort, Inc. announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010.

14 Oct 2010

Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation

Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease. This program is presently in clinical development phase II.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

An overview on Annual BioPartnering Europe 2010

TVG is pleased to welcome leading biotech and pharma executives at the 18th Annual BioPartnering Europe, held in London, UK. To open the conference, Dr. Anders Ekblom, Executive Vice President, Global Medicines Development at AstraZeneca, spoke about a commitment to innovation and AstraZeneca's unique approach to collaborations.

12 Oct 2010

Scripps Research study findings could transform drug development to produce more effective treatments

Scientists from The Scripps Research Institute have uncovered new evidence that challenges the current theory about a process key to the way modern drugs are designed and how they work in the human body.

12 Oct 2010

Researchers develop new method to identify chemical histone modifications

Test system on Drosophila should provide the key to histone function. The genetic inherited material DNA was long viewed as the sole bearer of hereditary information. The function of its packaging proteins, the histones, was believed to be exclusively structural. Additional genetic information can be stored, however, and passed on to subsequent generations through chemical changes in the DNA or histones. Scientists from the Max Planck Institute for Biophysical Chemistry in Göttingen have succeeded in creating an experimental system for testing the function of such chemical histone modifications and their influence on the organism.

12 Oct 2010

Biologists recommend virtual institute for RNA research

A Europe-wide network of labs focusing on RNA research is needed to make the most of RNA's high potential for treating a wide range of diseases. The recommendation for this virtual research institute comes from a panel of biologists at the European Science Foundation in a report published today, 'RNA World: a new frontier in biomedical research'.

12 Oct 2010

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

ArQule, Inc. today announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer (NSCLC) of non-squamous histology.

11 Oct 2010

Molecule News and Research

Researchers identify new mechanism that could help develop effective chemotherapy drug

Study finds IAP enzyme maintains normal microbial population in gastrointestinal system

Researchers to identify protein-recycling mechanism of TB bacteria

IDRI's TB vaccine protects against drug-resistant tuberculosis

Researchers identify new paradigm for regulation of alternative splicing

New insights into HIV infection process may allow antiviral drug development

Scientists discover mechanism of anticancer drug to kill cancer cells

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Scientists unveil quality control mechanism of immune system to destroy pathogens

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

An overview on Annual BioPartnering Europe 2010

Scripps Research study findings could transform drug development to produce more effective treatments

Researchers develop new method to identify chemical histone modifications

Biologists recommend virtual institute for RNA research

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News